Canada vs. Ireland: How the Tech Space Looks Either Side of the Atlantic

While the technological boom of the 21st century is a global phenomenon, it’s not evenly distributed across the globe. Some countries have much better developed tech scenes than others, and the situation is changing from decade to decade based on multiple factors. It’s not just the large nations that are leading the charge, as there are several medium-sized countries that punch far above their weight in this sector. Canada and Ireland are great examples, as both are home to numerous high-profile tech companies and have lots of native experts to perform crucial jobs.

We will take a closer look at these two countries located on the opposite sides of the Atlantic and compare their achievements in the technology domain. There are some obvious similarities but also many differences to explore, making this pairing very interesting.

Overview of the Canadian Technology Sector

From the earliest days of the IT revolution, Canada was on the forefront of innovation and business development. The population is highly educated and the nation has a well-regulated, business-friendly legal environment that benefits big technology firms. That has translated into a huge financial windfall – today the value of this industry exceeds $100 billion and it provides nearly 1.5 million jobs. Most of this is driven by the big players, including some globally known brands that many people don’t even know are Canadian. The list is headlined by names like Blackberry, Shopify, and Slack, but there are also brands such as Constellation Software Inc., CGI Inc., and many more.

Most of the tech industry is concentrated in large cities, with Ontario in particular being attractive to fast-growing start-ups due to great infrastructure and conscious efforts of the provincial leaders to attract investment. In recent years, the sector was invigorated by robust growth of the iGaming section with numerous Ontario online casino sites achieving international prominence. According to the available data, the growth is likely to continue into the foreseeable future and produce even more benefits for the local communities, although the competition is becoming stiffer. Canada has the foundation in place to remain a leader in the sector, but will have to adjust to new realities and continue supporting innovation and producing top talent to fill the key jobs.

Overview of the Irish Technology Sector

Ireland had a very different trajectory when it comes to the development of the technology sector. Back in the 1980’s when the industry first emerged as a global force, Ireland was still grappling with the complicated legacy of conflict and poverty. Things started changing for the better after the country successfully attracted international companies like Microsoft and Intel with a favourable tax regime, access to the common European market and other benefits. These and other blue chip companies opened their regional offices in Ireland, taking advantage of the tech-friendly legislation and turning the country into a vibrant hub. Smaller companies followed suit, while the influx of tech expertise also lead to development of some local success stories as well.

The industry accelerated in the 2010s, turning Ireland into a real force in the global market. The contributions of the technology sector to the nation’s finances today stand at 13% of the GDP, a much higher figure than in most countries of comparable size. Another incredible fact is that 16 out of 20 biggest tech companies in the world have an operating base in Ireland, with around 100,000 people employed in the sector. Some of the sub-fields with the strongest presence include FinTech and HealthTech, both of which are seen as extremely important in this period. That’s why it’s logical to expect Ireland to retain its unique position despite all the changes in the market.

Key Differences Between Europe and North America

There are certainly many parallels between Canada and Ireland when it comes to technology sector, but it would be naïve to assume that the situation is the same. As a North American country, the fortunes of Canada are closely tied to the United States and its powerful tech sector. It wouldn’t be fair to say that the Canadian tech industry lives in the shadow of the Silicon Valley, but the links are undeniable. Canada’s economy is also more diversified than Ireland’s, so the reliance on revenues from the tech sector is not nearly as dramatic. On the flip side, Canada’s location and climate may deter some of the most talented hardware and software engineers from joining companies based in the country.

Europe has its own set of issues that affect how Ireland conducts its tech business. The European Union consists of many nations, all of which have their local specificities. The regulations regarding fair competition and consumer protection are very strict, forcing tech companies to spend more to ensure compliance. Ireland has built a reputation as one of the most tech-friendly locations in Europe, yet it can’t truly be viewed outside of the broader EU context. It will be very interesting to see how the country navigates the changing political and economic climate and whether it will be able to leverage its experience with foreign corporations into a grassroots tech scene of its own.

DigiBio Healthtech Innovation Programme Offers €38,000, Mentorship

The DigiBio Healthtech Innovation Programme, designed to cultivate the next generation of innovators and entrepreneurs in the rapidly evolving health and wellbeing sectors, is now accepting applications for the second year of its ground-breaking innovation programme. Only 12 exceptional individuals from diverse backgrounds will be selected. Those who are passionate about innovation and delivering real impact are encouraged to apply.

Hosted and managed by Dundalk Institute of Technology (DkIT) in partnership with core partners RCSI University of Medicine and Health Sciences, Dublin City University, Trinity College Dublin and Tyndall National Institute, this transformative 10-month full-time postgraduate programme, commences in September 2025.

Programme Highlights:

  • €38,000 Scholarship: participants will receive €38,000 tax-free to participate in the programme
  • Expert Mentorship: participants will get invaluable guidance from experienced clinical, industry, investment and technology professionals
  • Comprehensive Training: hands-on training in needs-led innovation, design thinking and entrepreneurship will be provided
  • Direct Access to Healthcare Environments: participants will spend up to 8 weeks in a healthcare environment identifying real healthcare problems to address
  • Exploration of Commercial Opportunities: participants will be supported in developing and validating viable business propositions.

The current participants come from varied backgrounds and include a GP, nurse, physiotherapist, digital health designer, medical device designer, financial manager, digital transformation manager, and solicitor.

Carl Power, DigiBio Healthtech Innovation Programme Director, said:

“By providing aspiring innovators and entrepreneurs with the training, resources and support they need to succeed, this programme will play a vital role in shaping the future of healthcare with impactful solutions.

We are looking for 12 quality candidates, with five or more years of professional experience, who are looking to get into a start-up or perhaps a career change as an innovation leader. It’s a very hands-on programme where you also get direct access to healthcare environments. At its core, the programme is about learning and applying a specific approach to finding a problem worth solving and building a commercial case to bring it to market.”

DigiBio is supported under the Innovators’ Initiative Programme co-funded by the Government of Ireland and the European Union through the Southern, Eastern & Midland Regional Programme 2021-2027.

Applications are open until 2nd May. You can apply here – https://www.digibio.ie/apply#apply-now .

Health tech company Neurovalens raises more than £5 million for R&D and growth. #HealthTech #Belfast #Neurovalens

Neurovalens, a global healthtech company headquartered in Belfast and San Diego, has raised £5.1 million in funding, which will be used to expand on the success of its initial clinical trials and develop its technology’s application for other medical conditions.

The funding round was led by IQ Capital and also included investment from Wharton Asset Management Company, The Angel CoFund (ACF), Techstart Ventures, Co-Fund II managed by Clarendon Fund Managers and the UK Government’s Future Fund.

Neurovalens’ technology was created in collaboration with world renowned research facilities at the University of California San Diego. The vision of the company is to use technology that can influence the brainstem and hypothalamus in a non-invasive way to cure or treat neurological diseases, without the need for implanted electrodes.

 

CEO and co-founder of Neurovalens, Dr Jason McKeown said: “We are delighted to receive this investment and support at such a critical time for our business. Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions.”

The funding will be used for clinical trial research and development in the UK and abroad, as well as hiring additional staff. This will facilitate the development of Neurovalens’ technology – which is going through FDA and EU regulatory approvals – towards use as an approved medical treatment around the world. Neurovalens is already in the final phase of trials for obesity and aims to have approval for insomnia and anxiety devices in the next 12 months, with diabetes trials slated for 2021.

Kerry Baldwin, Managing Partner of IQ Capital commented: “IQ Capital is delighted to further support Neurovalens on their mission to deliver medical technology that can transform the lives of those who suffer from metabolic or neurological diseases. This funding will allow Neurovalens to accelerate their entry into the US healthcare system and to establish the technology as doctor-prescribed treatments for four of the biggest global health epidemics.”

Gaby Salem, Managing Director of Wharton Asset Management Company said: “This is a very exciting time for Neurovalens as they approach their first medical device approvals. This round of funding will enable Neurovalens to primarily focus on gaining traction within the US reimbursement sector while also continuing to develop the technology for further US FDA approvals.”

Tim Mills, Managing Partner of the Angel CoFund said: “The Neurovalens team have developed a truly innovative technique to help people combat an array of health challenges. As such, they are a rare example of a startup that really has the potential to fundamentally affect the sector they are in, changing how clinicians treat certain conditions. It is exciting to see the team at Neurovalens continue to grow and the success of their clinical trials, and we look forward to seeing the team continue to push boundaries in health tech.”

Techstart NI and Co-Fund II are part of Invest Northern Ireland’s Access to Finance portfolio and part funded by European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014-2020.

Brian Cummings from Clarendon Fund Managers, which manages Co-Fund II, added: “Neurovalens is a highly innovative company and it is testament to the interest the company’s technology has generated that they have been able to close this significant funding round. The business has scaled rapidly since launching in 2017 and we are excited that this investment will help Jason and his team to apply their technology to the treatment of additional health conditions and make a real difference.”

Jamie Andrews, Investor at Techstart Ventures said: “At Techstart Ventures we want to back really exciting early stage technology companies with expert founding teams. Over time some of these companies and teams can prove themselves to have true world class potential and persuade other more specialist funders to come alongside us. This financing round, led by IQ Capital, demonstrates Neurovalens are doing just that. We are again delighted to support the Neurovalens team as they enter an exciting new growth phase.”